Pfizer Inc

NYSE: PFE
$24.80
-$1.22 (-4.7%)
Closing Price on November 15, 2024

PFE Articles

Judging by the most shorted stocks traded on the New York Stock Exchange between the February 28 and March 15 settlement dates, short sellers were stocking up on some favorites.
DowDuPont, Goldman Sachs, 3M Company, and Pfizer pushed the Dow lower again Friday.
Pfizer shares slipped slightly on Friday after the pharma giant announced results from its Chantix/Champix smoking cessation study in adolescents.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
As of the most recently reported period, short sellers still favored just two Dow stocks, General Electric and Intel, above all others.
The Dow wobbled around Thursday and looks set to close very near the break-even line as J&J, Pfizer, Caterpillar, and McDonald's pushed higher.
The February 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
If the collaboration between Sangamo and Kite Pharma works out, some investors might just ask why Gilead did not just acquire Sangamo.
Pfizer, UnitedHealth, Disney, and Johnson & Johnson lifted the DJIA on Friday.
The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Four large-cap pharmaceutical leaders are rated Overweight at JPMorgan, and all make sense for growth accounts looking for some safety and income.
These are the 10 stocks tracked by 24/7 Wall St. that received multiple analyst rating upgrades or price target hikes of Wednesday, January 31, 2018.
The top analyst upgrades, downgrades and other research calls from Wednesday include AK Steel, Apple, Biogen, Electronic Arts, FitBit, Foot Locker, McDonald's and Pfizer.
UnitedHealth, Pfizer, McDonald's, and General Electric put in a dismal day and led the DJIA to steep loss Tuesday.
Pharmaceuticals giant Pfizer beat quarterly and full-year expectations this morning, but the beats were small and the forecast for next year is not exhilarating.